Due to significant study heterogeneity, current published reports cannot reliably estimate the true prevalence of primary aldosteronism, necessitating better-designed prevalence studies.
Existing prevalence estimates of primary aldosteronism remain unreliable for screening decisions; leaves open accurate burden pending standardized studies.
This study demonstrates that it is pointless to claim low or high prevalence of primary aldosteronism based on published reports. Because of the significant impact of a diagnosis of primary aldosteronism on health care resources and the necessary facilities, our findings urge for a prevalence study whose design takes into account the factors identified in the meta-regression analysis.
No takes yet. Share an insight, caveat, or question.
Käyser et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: